San Diego, USA-Recently, Jiaxing TechnoDerma Medicines Inc., a biotech company invested and incubated by Viva BioInnovator, announced that its phase I clinical trial of the world's leading small molecule drug TDM-105795 was successfully completed the first human administration (FIH) in healthy male subjects with androgenetic alopecia (AGA) in the skin clinical research center-TCR (Therapeutics Clinical Research), San Diego, U.S..TDM-105795 is a world-leading small molecule drug to treat the androgenetic alopecia with global intellectual property protection. At present, the phase I clinical trial of TDM-105795 has completed the subject screening, enrollment, and the first two subjects administration. It is expected that the phase I clinical dose-climbing trial will be completed in about three months.
TechnoDerma Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S.
May 11, 2021